Loading
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Regular session
$12.08
−$0.08 · -0.66%
Regular session · ET · Market data may be delayed.
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Day range
Current $12.08
52-week range
Current $12.08
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
14
Overpriced
Sentiment
63
Bullish
Risk
63
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.
Day range
Current $12.08
52-week range
Current $12.08
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$36.75
204.22% upsidePrice history unavailable
High $45.00Average $36.75Low $26.00Funds reporting this stock among their holdings, ordered by reported position size.
ALPS Medical Breakthroughs ETFSBIO957.64K0.39%245.3M USD0.50%$66.485-0.50%
Virtus Biotech Clinical Trials ETFBBC348.23K0.68%51.07M USD0.65%$52.935-0.44%
Fidelity Nasdaq Composite Index ETFONEQ305.94K—10.75B USD0.21%$103.79-0.32%
State Street SPDR S&P International Small Cap ETFGWX290.06K0.03%943.98M USD0.40%$46.86+0.24%
GlacierShares Nasdaq Iceland ETFGLCR97.44K6.49%1.5M USD0.95%$25.00-0.24%ALPS Medical Breakthroughs ETFSBIOVirtus Biotech Clinical Trials ETFBBCFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P International Small Cap ETFGWXGlacierShares Nasdaq Iceland ETFGLCRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
